Lmr Partners LLP Merus N.V. Transaction History

Lmr Partners LLP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$39.81 - $60.2 $159,240 - $240,800	4,000 New	4,000 $236,000
Q3 2022 Nov 14, 2022	SELL	$18.64 - $28.93 $442,103 - $686,161	-23,718 Reduced 44.99%	29,001 $581,000
Q2 2022 Aug 15, 2022	SELL	$13.98 - $29.25 $171,688 - $359,219	-12,281 Reduced 18.89%	52,719 $1.19 Million
Q1 2022 May 16, 2022	BUY	$23.58 - $30.91 $235,799 - $309,100	10,000 Added 18.18%	65,000 $1.72 Million
Q4 2021 Feb 14, 2022	BUY	$20.0 - $32.29 $1.1 Million - $1.78 Million	55,000 New	55,000 $1.75 Million

200

61.9M

243K

300K

Ticker MRUS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,878,200
Market Cap $2.28B
Description
Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase...

Get notified when there are updates to the investment portfolio of Lmr Partners LLP, based on Form 13F filings with the SEC.

Stay updated on Lmr Partners LLP with notifications on news.